Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Birth Control Methods

Birth Control Methods

Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although vasectomy...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Five-Year Experience of Haemophilia Centre Certification Performed by the German, Austrian and Swiss Society for Thrombosis and Haemostasis Research.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Health-Related Quality of Life in Adult Patients With von Willebrand Disease From Germany: Results of the WIL-QoL Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Clinical, Obstetric-Gynaecological and HRQoL Data of Female VWD Patients in the WIL-QoL Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Same author

Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry.

Thrombosis and haemostasis·2025

Same author

NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study.

BMJ open·2025

Same author

HAEMFIX: Impact of Switching From SHL-FIX to EHL-FIX in Patients With Haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

[Contraception and thrombophilia].

H Rott¹, A Kruempel, G Kappert

¹Ambulanz für Gerinnungsstörung/Hämophilie, MVZ Labor Duisburg GmbH, 47051 Duisburg, Germany.

Hamostaseologie

|May 1, 2009

Summary

Women with thrombophilia, a condition increasing clot risk, can safely use progestin-only contraceptives. These methods do not elevate the risk of thromboembolic events (TE) compared to other options.

Related Experiment Videos

Last Updated: Jun 23, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Area of Science:

Reproductive Health
Hematology

Background:

Thrombophilia increases the risk of thromboembolic events (TE).
Hormonal contraceptives can elevate thrombosis risk, posing a contraindication for women with thrombophilia.
Adolescents, though low-risk for TE, use hormonal contraception, increasing risk if thrombophilia is undiagnosed.

Purpose of the Study:

To evaluate the safety of contraceptive methods for women with thrombophilia.
To determine if progestin-only contraceptives are a suitable option for women with inherited or acquired thrombophilias.

Main Methods:

Review of existing literature on hormonal contraception and thrombophilia.
Analysis of coagulation protein changes associated with different contraceptive methods.

Main Results:

Progestin-only contraceptive methods show no significant increase in TE risk.
Moderate changes in coagulation proteins were observed with progestin-only methods, remaining within normal reference values.
Pregnancy alone carries a higher TE risk than combined hormonal contraception.

Conclusions:

Progestin-only contraceptives are a safe and recommended option for women with thrombophilia.
These methods offer a viable contraceptive choice without exacerbating clotting risks.